Notice sent to Glenmark’s Covid drug

The Central Drugs Standard Control Organisation (CDSCO)  has issued a show-cause notice to Glenmark over COVID drug Fabiflu . The notice is issued over false claims and pricing. It may be a generic version of Covid-19 drug favipiravir, Fabiflu has been approved.

The notice said,””Further, it has been mentioned in the representation that Glenmark has also claimed that this drug is effective in co-morbid conditions like hypertension, diabetes, whereas, in reality, as per protocol summary, this trial was not designed to assess the Fabiflu in co-morbid conditions. No clinically sufficient data specific to these conditions are available,”